In line with the negative correlation between Sirt1 and Scd1, Sharma et al. [76] showed that treatment with Barbamine, a compound that activated the SIRT1/LKB1/AMPK pathway prevented the elevation in the expression of FAS and SCD1 in the liver of rats with MASLD induced by HFD. This evidence concerns the gene FAS and metabolic dysfunction-associated steatotic liver disease.